Drug intelligence / Profile preview

CK0801

Development stage: Phase 2
Lead developer: Cellenkos
Modality: Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

CK0801 is an allogeneic T regulatory (Treg) cell therapy product derived from umbilical cord blood. It is designed to restore immune homeostasis by suppressing self-reactive T cells and interrupting the inflammatory loop in bone marrow failure syndromes. The therapy has shown promising results in treating conditions like aplastic anemia, myelofibrosis, and myelodysplastic syndromes, with patients achieving durable transfusion independence for up to 3.5 years. CK0801 is administered intravenously in an outpatient setting without requiring conditioning chemotherapy or hospitalization.

Other names: Cord blood derived T regulatory cellsUmbilical cord blood-derived CD4+/CD25+ T-regulatory cells

Beyond the preview

Go deeper on CK0801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CK0801.

Explore the full profile